IMbassador250
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
- NCT03016312 ↗
- Completed
- Hoffmann-La Roche
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on IMbassador250 (atezolizumab plus enzalutamide in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMbassador250 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Atezolizumab; Enzalutamide
- Arms
- Atezolizumab + Enzalutamide · Experimental
- Enzalutamide · Active comparator
- Enrollment
- 759
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche
- Start
- Jan 10, 2017
- Primary completion
- Jun 24, 2019
- Results posted
- Yes
- Registry record
- NCT03016312 · updated Aug 9, 2024
Publications
linked from the registry- Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, Drake CG, Fizazi K, Piulats JM, Wysocki PJ, Buchschacher GL Jr, Alekseev B, Mellado B, Karaszewska B, Doss JF, Rasuo G, Datye A, Mariathasan S, Williams P, Sweeney CJ. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022 Jan;28(1):144-153. doi: 10.1038/s41591-021-01600-6. Epub 2022 Jan 10. PubMed 35013615